Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna Stock Falls on Earnings Report. The Results Reaffirm a Grim Picture for Vaccine Maker.
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
FierceBiotech10h
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Moderna says norovirus vaccine trial on FDA clinical hold
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Moderna questioned on Trump, RFK Jr. impact on vaccine work
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
STAT4h
U.K. lawmaker wants regulators to probe pharma companies over ‘misleading’ Covid-19 vaccines statements
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
2MRNA : Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
Moderna Stock Falls After Vaccine Maker's Wider-Than-Expected Loss
Moderna shares fell after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2.91 per share, ...
No, Moderna Did Not Create Its COVID Vaccine Two Years Before the Pandemic
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
Moderna outlines $1.5B-$2.5B 2025 revenue target with focus on 10 product approvals
Earnings: Discover insights into revenue shifts, cost reductions, 2027 product goals, RSV market strategies, and its broader ...
FiercePharma6h
Moderna shoulders $238M contract manufacturing cancellation charge in Q4
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...